These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 2067035)

  • 1. Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study.
    Zalupski M; Metch B; Balcerzak S; Fletcher WS; Chapman R; Bonnet JD; Weiss GR; Ryan J; Benjamin RS; Baker LH
    J Natl Cancer Inst; 1991 Jul; 83(13):926-32. PubMed ID: 2067035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors.
    Casper ES; Gaynor JJ; Hajdu SI; Magill GB; Tan C; Friedrich C; Brennan MF
    Cancer; 1991 Sep; 68(6):1221-9. PubMed ID: 1873773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II evaluation of doxorubicin, ifosfamide, and dacarbazine plus amphotericin B in the treatment of metastatic soft tissue sarcomas. A pilot study.
    González-Manzano R; Vieitez JM; Tangco E; Fernandez de Alava E; Herranz P; Garcia-Foncillas J
    Am J Clin Oncol; 1993 Aug; 16(4):332-7. PubMed ID: 8328412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma--reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    Bramwell V; Rouesse J; Steward W; Santoro A; Schraffordt-Koops H; Buesa J; Ruka W; Priario J; Wagener T; Burgers M
    J Clin Oncol; 1994 Jun; 12(6):1137-49. PubMed ID: 8201375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy.
    Elias A; Ryan L; Sulkes A; Collins J; Aisner J; Antman KH
    J Clin Oncol; 1989 Sep; 7(9):1208-16. PubMed ID: 2504890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas. Swiss Group for Clinical Research (SAKK).
    Leyvraz S; Bacchi M; Cerny T; Lissoni A; Sessa C; Bressoud A; Hermann R
    Ann Oncol; 1998 Aug; 9(8):877-84. PubMed ID: 9789611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination chemotherapy using adriamycin, DTIC, cyclophosphamide, and actinomycin D for advanced soft tissue sarcomas: a randomized comparative trial. A phase III, Southwest Oncology Group Study (7613).
    Baker LH; Frank J; Fine G; Balcerzak SP; Stephens RL; Stuckey WJ; Rivkin S; Saiki J; Ward JH
    J Clin Oncol; 1987 Jun; 5(6):851-61. PubMed ID: 3295129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination chemotherapy with doxorubicin, dacarbazine, and ifosfamide in advanced adult soft tissue sarcoma. Canadian Sarcoma Group--National Cancer Institute of Canada Clinical Trials Group.
    Bramwell V; Quirt I; Warr D; Verma S; Young V; Knowling M; Eisenhauer E
    J Natl Cancer Inst; 1989 Oct; 81(19):1496-9. PubMed ID: 2778839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ifosfamide, vincristine, doxorubicin and dacarbazine in adult patients with advanced soft-tissue sarcoma.
    Wiklund TA; Blomqvist CP; Virolainen M; Elomaa I
    Cancer Chemother Pharmacol; 1992; 30(2):100-4. PubMed ID: 1600589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dana-Farber Cancer Institute studies in advanced sarcoma.
    Antman KH; Elias A
    Semin Oncol; 1990 Feb; 17(1 Suppl 2):7-15. PubMed ID: 2106162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
    Judson I; Verweij J; Gelderblom H; Hartmann JT; Schöffski P; Blay JY; Kerst JM; Sufliarsky J; Whelan J; Hohenberger P; Krarup-Hansen A; Alcindor T; Marreaud S; Litière S; Hermans C; Fisher C; Hogendoorn PC; dei Tos AP; van der Graaf WT;
    Lancet Oncol; 2014 Apr; 15(4):415-23. PubMed ID: 24618336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas.
    Borden EC; Amato DA; Rosenbaum C; Enterline HT; Shiraki MJ; Creech RH; Lerner HJ; Carbone PP
    J Clin Oncol; 1987 Jun; 5(6):840-50. PubMed ID: 3585441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of unresectable or metastatic pediatric soft tissue sarcomas with surgery, irradiation, and chemotherapy: a Pediatric Oncology Group study.
    Pratt CB; Maurer HM; Gieser P; Salzberg A; Rao BN; Parham D; Thomas PR; Marcus RB; Cantor A; Pick T; Green D; Neff J; Jenkins JJ
    Med Pediatr Oncol; 1998 Apr; 30(4):201-9. PubMed ID: 9473754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment results obtained in metastatic soft-tissue sarcoma with a combination of doxorubicin and dacarbazine or doxorubicin and ifosfamide.
    Weh HJ; Agarwal K; Zornig C; Schwarz R; Dietel M; Hossfeld DK
    Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S189-93. PubMed ID: 8453696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG).
    Toma S; Tucci A; Villani G; Carteni G; Spadini N; Palumbo R
    Anticancer Res; 2000; 20(1B):485-91. PubMed ID: 10769710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.
    Antman K; Crowley J; Balcerzak SP; Rivkin SE; Weiss GR; Elias A; Natale RB; Cooper RM; Barlogie B; Trump DL
    J Clin Oncol; 1993 Jul; 11(7):1276-85. PubMed ID: 8315425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study.
    García-Del-Muro X; López-Pousa A; Maurel J; Martín J; Martínez-Trufero J; Casado A; Gómez-España A; Fra J; Cruz J; Poveda A; Meana A; Pericay C; Cubedo R; Rubió J; De Juan A; Laínez N; Carrasco JA; de Andrés R; Buesa JM;
    J Clin Oncol; 2011 Jun; 29(18):2528-33. PubMed ID: 21606430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
    Lorigan P; Verweij J; Papai Z; Rodenhuis S; Le Cesne A; Leahy MG; Radford JA; Van Glabbeke MM; Kirkpatrick A; Hogendoorn PC; Blay JY;
    J Clin Oncol; 2007 Jul; 25(21):3144-50. PubMed ID: 17634494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    Santoro A; Tursz T; Mouridsen H; Verweij J; Steward W; Somers R; Buesa J; Casali P; Spooner D; Rankin E
    J Clin Oncol; 1995 Jul; 13(7):1537-45. PubMed ID: 7602342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Doxorubicin, ifosfamide, and dacarbazine (AID) with mesna uroprotection for advanced untreated sarcoma: a phase I study.
    Elias AD; Antman KH
    Cancer Treat Rep; 1986 Jul; 70(7):827-33. PubMed ID: 3087617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.